Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

Last updated: February 19, 2026
Sponsor: Western University, Canada
Overall Status: Active - Recruiting

Phase

4

Condition

Focal Segmental Glomerulosclerosis

Obesity

Kidney Failure

Treatment

Virtual Weight Management Coaching

Semaglutide

Clinical Study ID

NCT06396416
OK-TRANSPLANT 2
  • Ages > 18
  • All Genders

Study Summary

OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.

We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults aged 18 years or older

  • BMI > 35 kg/m^2

  • >10% risk of ESKD requiring renal replacement therapy over 2 years or receivingdialysis

Exclusion

Exclusion Criteria:

  • Known contraindication to a GLP-1RA

  • Type 1 diabetes

  • No access to semaglutide via drug coverage

  • Absolute contraindication to kidney transplant

  • Pregnant, breastfeeding or planning to become pregnant

  • Currently in a GLP-1RA or GLP-1RA/GIP study or planning to be in one

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Virtual Weight Management Coaching
Phase: 4
Study Start date:
September 26, 2024
Estimated Completion Date:
February 28, 2026

Study Description

Obesity is well-recognized as an independent risk factor for chronic kidney disease (CKD) including end-staged kidney disease (ESKD). In people with ESKD, obesity can preclude access to lifesaving kidney transplantation. Of solid organ transplant programs in Canada, 80% exclude people with obesity (based upon body mass index or BMI), due to a potential risk of perioperative complications and post-transplant mortality.

Losing weight for kidney transplantation can, however, be extremely difficult. Medications that can promote weight loss in other populations including glucagon-like peptide 1 receptor agonists (GLP-1RA; liraglutide, semaglutide, and dulaglutide) and glucose-dependent insulinotropic polypeptide (GIP-1RA)/GLP-1RAs (tirzepatide), have not been studied in devoted trials of advanced CKD participants, and their efficacy and safety remain unclear.

Nutritional advice is often very difficult to follow when trying to balance kidney and diabetes diets (e.g. potassium), and if diets are too restrictive, there may be protein-energy wasting which could be detrimental to patients. People with high-risk CKD frequently live with functional impairment which can limit exercise. Weight loss programs can be cost prohibitive to those who are already socioeconomically disadvantaged.

A vanguard is needed before a large, multicentered RCT: A feasibility study will allow us to ensure that we can recruit a sufficient sample of participants into our trial, that our trial processes are inclusive, and that they are acceptable to patients. In the vanguard phase of our trial, we will answer the following questions:

  1. Is participant recruitment into a large multi-centered trial feasible?

  2. Will participants remain adherent to their assigned treatment arm over 26 weeks of study?

  3. Will participants find our program acceptable?

  4. Will safety events preclude us from testing our intervention in a larger RCT?

Connect with a study center

  • London Health Sciences Centre

    London, Ontario N6A 5A5
    Canada

    Site Not Available

  • London Health Sciences Centre

    London 6058560, Ontario 6093943 N6A 5A5
    Canada

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.